MG1141A As a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Dec 6

PMID 34868052

Citations 2

Authors

Sua Lee

Shina Jang

Jihoon Kang

Soo Bin Park

Young Woo Han

Hyemi Nam

Munkyung Kim

Jeewon Lee

Ki Joon Cho

Jeonghun Kim

Miyoung Oh

Jihye Ryu

Jong Hyeon Seok

Yunhwa Kim

Jee-Boong Lee

Man-Seong Park

Yong-Sung Kim

Hosun Park

Dong-Sik Kim

Affiliations

Soon will be listed here.

Abstract

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.

Citing Articles

Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective.

Bhattacharya M, Chatterjee S, Mallik B, Sharma A, Chakraborty C Vaccines (Basel). 2022; 10(10).

PMID: 36298477 PMC: 9606861. DOI: 10.3390/vaccines10101612.

Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins.

Matesic M, Kucan Brlic P, Lenac Rovis T, Macak Safranko Z, Chaouat A, Miklic K Viruses. 2022; 14(2).

PMID: 35216036 PMC: 8875891. DOI: 10.3390/v14020443.

References

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

Taylor P, Adams A, Hufford M, de la Torre I, Winthrop K, Gottlieb R . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21(6):382-393. PMC: 8054133. DOI: 10.1038/s41577-021-00542-x. View

Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J . SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):229-237. PMC: 7646625. DOI: 10.1056/NEJMoa2029849. View

Eguia R, Crawford K, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger A, Englund J . A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021; 17(4):e1009453. PMC: 8031418. DOI: 10.1371/journal.ppat.1009453. View

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C . Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011; 333(6049):1593-602. PMC: 3516815. DOI: 10.1126/science.1207532. View

Goodwin E, Gilman M, Wrapp D, Chen M, Ngwuta J, Moin S . Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity. 2018; 48(2):339-349.e5. PMC: 6005179. DOI: 10.1016/j.immuni.2018.01.005. View

Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta G . Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A. 2009; 106(48):20216-21. PMC: 2787155. DOI: 10.1073/pnas.0909775106. View

Burioni R, Topol E . Assessing the human immune response to SARS-CoV-2 variants. Nat Med. 2021; 27(4):571-572. DOI: 10.1038/s41591-021-01290-0. View

10.

Lundgren J, Grund B, Barkauskas C, Holland T, Gottlieb R, Sandkovsky U . A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(10):905-914. PMC: 7781100. DOI: 10.1056/NEJMoa2033130. View

11.

Hansen J, Baum A, Pascal K, Russo V, Giordano S, Wloga E . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020; 369(6506):1010-1014. PMC: 7299284. DOI: 10.1126/science.abd0827. View

12.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

13.

Zost S, Gilchuk P, Chen R, Case J, Reidy J, Trivette A . Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020; 26(9):1422-1427. PMC: 8194108. DOI: 10.1038/s41591-020-0998-x. View

14.

Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y . SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021; 29(4):522-528.e2. PMC: 7980135. DOI: 10.1016/j.chom.2021.03.008. View

15.

Lee C, Amrun S, Chee R, Goh Y, Mak T, Octavia S . Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. Clin Transl Immunology. 2021; 10(2):e1241. PMC: 7899292. DOI: 10.1002/cti2.1241. View

16.

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

17.

Andreano E, Rappuoli R . SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nat Med. 2021; 27(5):759-761. DOI: 10.1038/s41591-021-01347-0. View

18.

Asokan M, Dias J, Liu C, Maximova A, Ernste K, Pegu A . Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc Natl Acad Sci U S A. 2020; 117(31):18754-18763. PMC: 7414046. DOI: 10.1073/pnas.2008236117. View

19.

Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D . Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Inflammation. 2020; 44(1):13-34. PMC: 7541099. DOI: 10.1007/s10753-020-01337-3. View

20.

Wang Y, Liu L . The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Functions as a Novel Cytosolic Pathogen-Associated Molecular Pattern To Promote Beta Interferon Induction via a Toll-Like-Receptor-Related TRAF3-Independent Mechanism. mBio. 2016; 7(1):e01872-15. PMC: 4752600. DOI: 10.1128/mBio.01872-15. View